All In Biotech

Free tool

FAERS Monitor: Focalin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021278 or its brand name (Focalin, Dexmethylphenidate Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

2,943

Serious

992

34% of reports

Hospitalization

286

Death reported

23

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective565
  • nausea158
  • anxiety151
  • fatigue139
  • off label use129
  • headache126
  • feeling abnormal122
  • disturbance in attention112
  • insomnia111
  • decreased appetite110
  • vomiting109
  • abnormal behaviour104
  • dizziness100
  • aggression98
  • depression96

Reports by year received

View as table
YearReports
200414
200519
200626
200739
200839
200950
201052
201177
201284
201375
201485
2015260
2016301
2017235
2018184
2019217
2020157
2021117
2022176
2023205
2024186
2025187
2026158

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,216 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
abnormal behaviourSignal10418.815.61,735
disturbance in attentionSignal11214.912.41,436
aggressionSignal9814.011.51,172
anxietySignal1513.83.2312
feeling abnormalSignal1223.63.1233
decreased appetiteSignal1103.42.8184
drug ineffectiveSignal5653.12.8836
depressionSignal963.02.5129
insomniaSignal1113.02.5146
vomiting1091.71.428
headache1261.41.217
dizziness1001.41.213
nausea1581.41.221
fatigue1391.31.18
off label use1291.10.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.